Bioactivity | SRT 1720 dihydrochloride is a selective and orally active activator of SIRT1 with an EC50 of 0.10 μM, and shows less potent activities on SIRT2 and SIRT3[1]. | ||||||||||||
Invitro | 即使在没有 SIRT1 的情况下,SRT 1720 dihydrochloride 也能有效地降低细胞中 p53 的乙酰化,这归因于组蛋白乙酰转移酶 p300[2]。 | ||||||||||||
In Vivo | SRT 1720 (10, 30, 100 mg/kg, p.o.) dihydrochloride 处理显著降低 Lepob/ob 小鼠的空腹血糖至接近正常水平[1]。SRT 1720 dihydrochloride 能够保护小鼠免受饮食诱导的肥胖的负面影响,并通过 SIRT1 的下游靶点,如 PGC1α 和 FOXO1,与脂肪酸和氧化代谢的代谢适应有关[2]。 SRT 1720 (50-100 mg/kg, p.o.) dihydrochloride 在肺气肿发展过程中减弱弹性酶诱导的气道扩大和肺功能损害,并降低野生小鼠的动脉氧饱和度[3]。 | ||||||||||||
Name | SRT 1720 dihydrochloride | ||||||||||||
CAS | 2468639-77-0 | ||||||||||||
Formula | C25H25Cl2N7OS | ||||||||||||
Molar Mass | 542.48 | ||||||||||||
Appearance | Solid | ||||||||||||
Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
Storage |
|
||||||||||||
Reference | [1]. Milne JC et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007 Nov 29;450(7170):712-6 [2]. Baur JA, et al. Are sirtuins viable targets for improving healthspan and lifespan?,Nat Rev Drug Discov. 2012 Jun 1;11(6):443-61 [3]. Yao H, et al. SIRT1 protects against emphysema via FOXO3-mediated reduction of premature senescence in mice.,J Clin Invest. 2012 Jun 1;122(6):2032-45. [4]. Gao D, et al. Activation of SIRT1 Attenuates Klotho Deficiency-Induced Arterial Stiffness and Hypertension by Enhancing AMP-Activated Protein Kinase Activity. Hypertension. 2016 Nov;68(5):1191-1199. [5]. Lahusen TJ, et al. SRT1720 induces lysosomal-dependent cell death of breast cancer cells. Mol Cancer Ther. 2015 Jan;14(1):183-92. |